Ticagrelor

Chemical formula: C₂₃H₂₈F₂N₆O₄S  Molecular mass: 522.568 g/mol  PubChem compound: 9871419

Therapeutic indications

Ticagrelor is indicated for:

Prevention of atherothrombotic events in history of myocardial infarction (MI)

Population group: only adults (18 years old or older)

Ticagrelor, co-administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with a history of myocardial infarction (MI) and a high risk of developing an atherothrombotic event.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Prevention of atherothrombotic events in acute coronary syndromes (ACS)

Ticagrelor, co-administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with acute coronary syndromes (ACS).

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Ticagrelor is contraindicated in the following cases:

Active pathological bleeding

Bleeding

History of intracranial haemorrhage

History of cerebral hemorrhage

Severe hepatic impairment

Hepatic failure stage IV

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Structured Product Labeling (SPL/PLR) 2021: BRILINTA Film-coated tablet
Summary of Product Characteristics (SPC) 2019: BRILIQUE Film-coated tablet
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈